Background & aimsNon-invasive biomarkers are needed for monitoring changes in liver histology in patients with non-alcoholic steatohepatitis (NASH). Obeticholic acid (OCA) was shown to improve fibrosis in patients with NASH in the FLINT trial; a post hoc analysis of these data was performed to determine the relationship between 3 non-invasive fibrosis markers and liver fibrosis improvement.MethodsIn the Phase 2b FLINT trial, patients were randomised (1:1) to receive 25 mg OCA or placebo once daily for 72 weeks. Aspartate aminotransferase:platelet ratio index (APRI), fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease fibrosis score (NFS) were evaluated in serum at baseline and weeks 24, 48, 72 and 96. Liver biopsies...
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
Background & aimsFALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic s...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
BACKGROUND & AIMS: Non-invasive biomarkers are needed for monitoring changes in liver histology in p...
BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver di...
Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced fibros...
Background and Aims: In nonalcoholic steatohepatitis (NASH), the main factor associated with hepatic...
Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fi...
Patient‐reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
Surrogate endpoints that predict complications are necessary for assessment and approval of NASH the...
Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
Surrogate endpoints that predict complications are necessary for assessment and approval of NASH the...
Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
The term non-alcoholic fatty liver disease (NAFLD) comprises at least four pathological entities (de...
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
Background & aimsFALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic s...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...
BACKGROUND & AIMS: Non-invasive biomarkers are needed for monitoring changes in liver histology in p...
BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver di...
Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced fibros...
Background and Aims: In nonalcoholic steatohepatitis (NASH), the main factor associated with hepatic...
Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fi...
Patient‐reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
Surrogate endpoints that predict complications are necessary for assessment and approval of NASH the...
Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
Surrogate endpoints that predict complications are necessary for assessment and approval of NASH the...
Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
The term non-alcoholic fatty liver disease (NAFLD) comprises at least four pathological entities (de...
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can ...
Background & aimsFALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic s...
Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the United...